Letters to the Editor

Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies

BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
Texas Oncology Baylor Charles A. Sammons Cancer Center, Dallas, TX
SSM Health Dean Medical Group, Madison, WI
Rocky Mountain Cancer Centers, Aurora, CO
Florida Cancer Specialists and Research Institute, Fort Myers, FL
Florida Cancer Specialists and Research Institute, Leesburg, FL
Medical Oncology Hematology Consultants PA, Newark, DE
Comprehensive Cancer Centers of Nevada, Las Vegas, NV
Texas Oncology, Tyler, TX
Summit Medical Group, Florham Park, NJ
Summit Cancer Centers, Spokane, WA
Texas Oncology, Amarillo, TX
Virginia Cancer Specialists, Gainesville, VA
BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA
BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA
BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA
BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA
BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA
Arizona Oncology / US Oncology Research, Tucson, AZ, USA; and
Willamette Valley Cancer Institute and Research Center, Eugene, OR
BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA
Haematologica Early view Jan 25, 2024 https://doi.org/10.3324/haematol.2023.283861